Home
Kolon Life Science

Kolon Life Science Market Share Analysis for August 2026

세포 매개성 유전자 치료제 인보사 ㅣ 신약 개발과 상업화를 통한 바이오 선도 기업으로 성장, 전세계 환우들의 삶의 질 증진에 기여합니다.

Health > Biotechnology and Pharmaceuticals

Domainkolonls.co.kr

Year Founded2000

Employees201 - 500

Annual Revenue$100M - $200M

Kolon Life Science

Kolon Life Science (including company regionals)

kolonls.co.kr

See more website traffic and engagement information

Kolon Life Science Revenue up to August 2026 is 100M - 200M

revenue generated by Kolon Life Science top domains

Kolon Life Science top domains revenue over 3 years

Revenue for Kolon Life Science top domains

kolonls.co.kr100M - 200M

See more with Sales Intelligence

Total visits to Kolon Life Science's top domains

Understand Kolon Life Science market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kolonls.co.kr5.2K

See more with Sales Intelligence

Avg. visit duration in Kolon Life Science's top domains

Analyze Kolon Life Science engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kolonls.co.kr00:00:40

See more with Sales Intelligence

Avg. pageviews on Kolon Life Science's top domains

See how Kolon Life Science keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kolonls.co.kr5.29

See more with Sales Intelligence

Kolon Life Science top competitors by domain

Top similar sites in August 2026, ranked by their affinity

helixmith.comCompany NameHelixmithEmployees51 - 200HQKorea, Republic of, Gangseo-guAnnual revenue--Total visits1.9KHealth > Health Conditions and Concerns

Top technologies used by Kolon Life Science

These are the website technologies, by industry, used by Kolon Life Science top domains

Advertising (2)

DoubleClick

Conversion & Analytics (2)

Google Analytics

Marketing (1)

Google Marketing Platform

Mobile (1)

Meta Viewport

More Technologies

2

See all

News & Signals from Kolon Life Science

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKOLON Life Science, Inc. is developing KLS-3021 on May 27th '26.Kolon Life Science Inc. is developing KLS-3021, a next-generation oncolytic vaccinia virus designed to express the PH20, IL-12 and PD-1-Fc transgenes to mediate receptor-independent tumor cell killing and enhance antitumor immune responses.

NewsKOLON Life Science, Inc. is developing Invossa-K between 2015 and 2018.The government invested 8.21 billion won ($6.9 million) in healthcare-related research institutes to help Kolon Life Science develop Invossa-K between 2015 and 2018.

NewsKOLON Life Science, Inc. files suit against Ministry of Food and Drug Safety.Kolon filed the administrative suit against the Ministry of Food and Drug Safety to invalidate the ministry’s order to nullify the Invossa license.